De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

INTRODUCTION: Anaplastic lymphoma kinase (ALK) rearranged lung adenocarcinomas are responsive to the multitargeted ALK inhibitor crizotinib. One of the common mechanisms of resistance to crizotinib is the acquisition of ALK kinase domain mutations. However, the presence of ALK mutations in crizotini...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lung Cancer
Egile Nagusiak: Lucena-Araujo, Antonio R., Moran, Jason P., VanderLaan, Paul A., Dias-Santagata, Dora, Folch, Erik, Majid, Adnan, Kent, Michael S., Gangadharan, Sidharta P., Rangachari, Deepa, Huberman, Mark S., Kobayashi, Susumu S., Costa, Daniel B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5002311/
https://ncbi.nlm.nih.gov/pubmed/27565908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2016.06.006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak